Emerging CAR-T Therapies in Large B-cell Lymphomas (LBCL): Highlights from ASH 2022 and Beyond

Experts review key updates in LBCL management from the ASH 2022 annual meeting.

EP. 1: Overview of Large B-Cell Lymphoma (LBCL)

January 24th 2023

Experts discuss Large B-Cell Lymphoma (LBCL) and treatment strategies for patients with LBCL.

EP. 2: Treatment Strategies for Patients with R/R LBCL

January 24th 2023

Experts provide their perspective on the treatment landscape for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

EP. 3: CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies

January 24th 2023

In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

EP. 4: CAR T-Cell Therapy as Second-Line Treatment in LBCL

February 2nd 2023

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

EP. 5: Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

February 2nd 2023

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

EP. 6: Additional Key Data Updates from ASH 2022 on Treatment of LBCL

February 2nd 2023

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

EP. 7: Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

February 2nd 2023

Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting,

EP. 8: Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

February 2nd 2023

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.